Evidence map›Paper›PMID 38927605›Full record

ArticleGenes2024

Association of

Nurgul Sikhayeva, Aidos Bolatov, Elena Zholdybayeva, Ilyas Akhmetollayev, Aisha Iskakova

Abstract read
In one paragraph

Article in Genes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nurgul Sikhayeva"National Center for Biotechnology" LLP, JSC National Holding "Qazbiopharm", Korgalzhyn 13/1, Astana 010000, Kazakhstan.ORCID 0000-0001-6419-9483
Aidos BolatovSchool of Medicine, Astana Medical University, Beibitshilik 49a, Astana 010000, Kazakhstan.ORCID 0000-0002-5390-4623
Elena Zholdybayeva"National Center for Biotechnology" LLP, JSC National Holding "Qazbiopharm", Korgalzhyn 13/1, Astana 010000, Kazakhstan.ORCID 0000-0002-9677-008X
Ilyas Akhmetollayev"National Center for Biotechnology" LLP, JSC National Holding "Qazbiopharm", Korgalzhyn 13/1, Astana 010000, Kazakhstan.
Aisha Iskakova"National Center for Biotechnology" LLP, JSC National Holding "Qazbiopharm", Korgalzhyn 13/1, Astana 010000, Kazakhstan.ORCID 0000-0002-0631-062X

Funding

the Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan АР09057948
6 · The paper itself

Abstract

Type 2 diabetes mellitus (T2DM) is a socially significant disease with increasing prevalence worldwide. It is characterized by heterogeneous metabolic disorders and is associated with various risk factors, including BMI, abnormal lipid levels, hypertension, smoking, dietary preferences, physical inactivity, sedentary lifestyle, family history of diabetes, prediabetes or gestational diabetes, inflammation, intrauterine environment, age, sex, ethnicity, and socioeconomic status. Assessing the genetic risk of developing T2DM in specific populations remains relevant. The

Indexed as

AdiponectinDiabetes Mellitus, Type 2Genetic Predisposition to DiseaseObesityPolymorphism, Single NucleotideAdultAgedCase-Control StudiesFemaleHumansKazakhstanMaleMiddle AgedRisk FactorsAdiponectinADIPOQ protein, humanADIPOQ genediabetes riskgenetic factorsobesitySNPtype 2 diabetes

Identifiers

PMID38927605
PMCPMC11203345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.